Skip to content

Michael T. Faley

Usona Institute

2 papers in the library · 1 citation · publishing 2025-2026

Papers

Synthesis of Psilocin, Psilocybin and 5‐MeO‐DMT Succinate, All Labelled With Carbon‐14 at the Indole 2‐Position

Journal of Labelled Compounds and Radiopharmaceuticals July 1, 2025 Rodney D. Brown, Niall M. Hamilton, Connor Mallon et al. 1 citation

Three new radiolabelled versions of the psychedelic compounds psilocin, psilocybin, and 5-MeO-DMT were synthesized, each with carbon-14 at the 2-position of the indole ring. The synthesis used a common route: attaching the dimethylaminoethyl side chain to substituted indole intermediates via oxalyl chloride, dimethylamine, and lithium aluminium hydride reduction. Psilocybin-2-14C at 234 μCi/mg showed limited stability, but a 5.5-fold dilution with unlabelled psilocybin maintained >97.5% radiochemical purity after one month at ≤−70°C. 5-MeO-DMT-2-14C succinate at 173 μCi/mg remained 98.0% pure after six months at ≤−70°C, supporting long-term studies. These labelled compounds enable in vivo pharmacokinetic and metabolic studies of psychedelic tryptamines, aiding ADME and mass balance research for potential regulatory approval in treating depression, anxiety, and PTSD.

Synthesis and Characterization of Psilocybin Metabolites and Deuterated Analogs

ACS Chemical Neuroscience March 3, 2026 Samuel E. Williamson, Elise K. Burkhartzmeyer, Michael T. Faley et al.

To support ongoing clinical trials, the major human metabolites of psilocybin—psilocin-O-glucuronide and 4-hydroxyindole-3-acetic acid (4-HIAA)—along with putative minor metabolites and several deuterium-labeled derivatives, were synthesized on a preparative scale. When assayed for engagement at seven serotonin receptor subtypes using a BRET-based binding assay, only psilocin exhibited any discernible binding. Given the high cost and challenging preparation of these compounds, the work provides a comprehensive guide for researchers to access these resources, advancing both basic and clinical research with psilocybin and its metabolites.